[
  {
    "ts": null,
    "headline": "Here's Why Pfizer (PFE) Fell More Than Broader Market",
    "summary": "In the latest trading session, Pfizer (PFE) closed at $25.24, marking a -1.71% move from the previous day.",
    "url": "https://finnhub.io/api/news?id=63d3b380f3ba812da2041495bcc73ab4f42b5a06692d75fbe7e55792b14b88e8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760046304,
      "headline": "Here's Why Pfizer (PFE) Fell More Than Broader Market",
      "id": 137041823,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "In the latest trading session, Pfizer (PFE) closed at $25.24, marking a -1.71% move from the previous day.",
      "url": "https://finnhub.io/api/news?id=63d3b380f3ba812da2041495bcc73ab4f42b5a06692d75fbe7e55792b14b88e8"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Declares Fourth-Quarter 2025 Dividend",
    "summary": "NEW YORK, October 09, 2025--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2025 dividend on the company’s common stock, payable December 1, 2025, to holders of the Common Stock of record at the close of business on November 7, 2025. The fourth-quarter 2025 cash dividend will be the 348th consecutive quarterly dividend paid by Pfizer.",
    "url": "https://finnhub.io/api/news?id=357b6add9608000159ef287c71b1ae762cad514926f6a6e43ee769103ff44acb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760041800,
      "headline": "Pfizer Declares Fourth-Quarter 2025 Dividend",
      "id": 137041824,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, October 09, 2025--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2025 dividend on the company’s common stock, payable December 1, 2025, to holders of the Common Stock of record at the close of business on November 7, 2025. The fourth-quarter 2025 cash dividend will be the 348th consecutive quarterly dividend paid by Pfizer.",
      "url": "https://finnhub.io/api/news?id=357b6add9608000159ef287c71b1ae762cad514926f6a6e43ee769103ff44acb"
    }
  },
  {
    "ts": null,
    "headline": "CompoSecure Appoints Mary Holt as Chief Financial Officer",
    "summary": "Brings a wealth of financial leadership from world-class organizations such as Honeywell and PfizerSOMERSET, N.J., Oct. 09, 2025 (GLOBE NEWSWIRE) -- CompoSecure, Inc. (NYSE: CMPO), a leader in metal payment cards, security, and authentication solutions, today announced the appointment of Mary Holt as Chief Financial Officer (CFO), effective the day immediately following the filing of the Company's Q3 2025 Quarterly Report. She succeeds Tim Fitzsimmons who is retiring after a distinguished career",
    "url": "https://finnhub.io/api/news?id=9a1304ff5f757813a63b5d4ec8d7d623ab297b7afd8aefcc227c627658bf6e27",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760040900,
      "headline": "CompoSecure Appoints Mary Holt as Chief Financial Officer",
      "id": 137041825,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Brings a wealth of financial leadership from world-class organizations such as Honeywell and PfizerSOMERSET, N.J., Oct. 09, 2025 (GLOBE NEWSWIRE) -- CompoSecure, Inc. (NYSE: CMPO), a leader in metal payment cards, security, and authentication solutions, today announced the appointment of Mary Holt as Chief Financial Officer (CFO), effective the day immediately following the filing of the Company's Q3 2025 Quarterly Report. She succeeds Tim Fitzsimmons who is retiring after a distinguished career",
      "url": "https://finnhub.io/api/news?id=9a1304ff5f757813a63b5d4ec8d7d623ab297b7afd8aefcc227c627658bf6e27"
    }
  },
  {
    "ts": null,
    "headline": "A Major Eli Lilly Shareholder Has Sold Stock Nearly Every Day in October. Here’s Who It Is.",
    "summary": "A nonprofit founded by members of the Lilly family has been unloading  Eli Lilly  stock nearly every day since the start of the month.  Of the first six trading days in October, the Lilly Endowment has made sales on five of them.  The most recent transaction came on Oct. 7, when the Lilly Endowment sold 26,795 shares of common stock for an average of $848 each, or $22.7 million in total, according to a Form 4 filed with the Securities and Exchange Commission.",
    "url": "https://finnhub.io/api/news?id=ae4422e734ed829f05ec717b21f6bd4ddb255dfbfd2b90bf6a6ca48bc869b4ef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760037960,
      "headline": "A Major Eli Lilly Shareholder Has Sold Stock Nearly Every Day in October. Here’s Who It Is.",
      "id": 137041438,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "A nonprofit founded by members of the Lilly family has been unloading  Eli Lilly  stock nearly every day since the start of the month.  Of the first six trading days in October, the Lilly Endowment has made sales on five of them.  The most recent transaction came on Oct. 7, when the Lilly Endowment sold 26,795 shares of common stock for an average of $848 each, or $22.7 million in total, according to a Form 4 filed with the Securities and Exchange Commission.",
      "url": "https://finnhub.io/api/news?id=ae4422e734ed829f05ec717b21f6bd4ddb255dfbfd2b90bf6a6ca48bc869b4ef"
    }
  },
  {
    "ts": null,
    "headline": "Why Shares in Viking Therapeutics Surged This Week",
    "summary": "The small-cap pharmaceutical company may be the next in line as takeover fever heats up.",
    "url": "https://finnhub.io/api/news?id=d42cc8e2ab205342fe84da7bf88aaac0e49b9cc5d347b36d16eb935ed7f6f3c0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760031457,
      "headline": "Why Shares in Viking Therapeutics Surged This Week",
      "id": 137034231,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The small-cap pharmaceutical company may be the next in line as takeover fever heats up.",
      "url": "https://finnhub.io/api/news?id=d42cc8e2ab205342fe84da7bf88aaac0e49b9cc5d347b36d16eb935ed7f6f3c0"
    }
  },
  {
    "ts": null,
    "headline": "GSK's Hidden Growth Engines Beyond HIV And Oncology",
    "summary": "GSK plcâs strong oncology growth, highlighted by Ojjaara sales and an upgraded 2025 outlook, earns a continued 'Buy' rating. Learn more about GSK stock here.",
    "url": "https://finnhub.io/api/news?id=ee4aebd4250ddb46bf7735456b5f1abe9d3ddd42dfabc80b324a2accb000cca8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760016130,
      "headline": "GSK's Hidden Growth Engines Beyond HIV And Oncology",
      "id": 137032881,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1193052383/image_1193052383.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "GSK plcâs strong oncology growth, highlighted by Ojjaara sales and an upgraded 2025 outlook, earns a continued 'Buy' rating. Learn more about GSK stock here.",
      "url": "https://finnhub.io/api/news?id=ee4aebd4250ddb46bf7735456b5f1abe9d3ddd42dfabc80b324a2accb000cca8"
    }
  },
  {
    "ts": null,
    "headline": "ViiV Healthcare showcases breadth of clinical and real-world evidence at EACS and IDWeek 2025",
    "summary": "LONDON, October 09, 2025--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of more than 60 abstracts, including data from its industry-leading long-acting HIV treatment and prevention portfolio, at the 20th European AIDS Conference (EACS) in Paris, France from 15-18 October, and at IDWeek 2025 in Atlanta, Georgia, US from 19-22 October.",
    "url": "https://finnhub.io/api/news?id=055acc4d59cc2ad7a2fdd2df76b8afd5bee0520cd7343a2b638c9e98b98c45d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760014800,
      "headline": "ViiV Healthcare showcases breadth of clinical and real-world evidence at EACS and IDWeek 2025",
      "id": 137033406,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "LONDON, October 09, 2025--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of more than 60 abstracts, including data from its industry-leading long-acting HIV treatment and prevention portfolio, at the 20th European AIDS Conference (EACS) in Paris, France from 15-18 October, and at IDWeek 2025 in Atlanta, Georgia, US from 19-22 October.",
      "url": "https://finnhub.io/api/news?id=055acc4d59cc2ad7a2fdd2df76b8afd5bee0520cd7343a2b638c9e98b98c45d5"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: Your Chance To Buy A Bargain 6% Yield",
    "summary": "Discover why Bristol-Myers Squibb (BMY) is a top value stock pick with strong growth prospects and a 6% dividend yield.",
    "url": "https://finnhub.io/api/news?id=1a26e9971307300fdbef15159c4319b7b973c8e487e33ad3832119cce7e5826f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760011231,
      "headline": "Bristol-Myers Squibb: Your Chance To Buy A Bargain 6% Yield",
      "id": 137032548,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1424217301/image_1424217301.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover why Bristol-Myers Squibb (BMY) is a top value stock pick with strong growth prospects and a 6% dividend yield.",
      "url": "https://finnhub.io/api/news?id=1a26e9971307300fdbef15159c4319b7b973c8e487e33ad3832119cce7e5826f"
    }
  },
  {
    "ts": null,
    "headline": "My Dividend Stock Portfolio: New September Dividend Record - 100 Holdings With 13 Buys",
    "summary": "Discover September's top stock gains, AI-driven strategies, and high-yield BDC investments to boost passive income.",
    "url": "https://finnhub.io/api/news?id=8d23a2abebc98961046aa372ed04c412898c62c1483cedde798fbcf32b86519f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760004000,
      "headline": "My Dividend Stock Portfolio: New September Dividend Record - 100 Holdings With 13 Buys",
      "id": 137032129,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213764535/image_1213764535.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover September's top stock gains, AI-driven strategies, and high-yield BDC investments to boost passive income.",
      "url": "https://finnhub.io/api/news?id=8d23a2abebc98961046aa372ed04c412898c62c1483cedde798fbcf32b86519f"
    }
  },
  {
    "ts": null,
    "headline": "Bispecific Antibodies Market - Global Forecast 2025-2032, Profiles of Key Players - F. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab",
    "summary": "The bispecific antibodies market presents key opportunities in oncology, autoimmune, and infectious diseases, driven by rapid technological advancements and strategic collaborations. Regional manufacturing and diverse supplier networks optimize supply chains, while innovation in antibody structures supports tailored therapies. Bispecific Antibodies Market Bispecific Antibodies Market Dublin, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The \"Bispecific Antibodies Market - Global Forecast 2025-2032\" report h",
    "url": "https://finnhub.io/api/news?id=d1948cb61301d64f144bdf4db2d55b6472eca18c5b1637ffc6ab4dc18bf7a5a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759998180,
      "headline": "Bispecific Antibodies Market - Global Forecast 2025-2032, Profiles of Key Players - F. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab",
      "id": 137029703,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The bispecific antibodies market presents key opportunities in oncology, autoimmune, and infectious diseases, driven by rapid technological advancements and strategic collaborations. Regional manufacturing and diverse supplier networks optimize supply chains, while innovation in antibody structures supports tailored therapies. Bispecific Antibodies Market Bispecific Antibodies Market Dublin, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The \"Bispecific Antibodies Market - Global Forecast 2025-2032\" report h",
      "url": "https://finnhub.io/api/news?id=d1948cb61301d64f144bdf4db2d55b6472eca18c5b1637ffc6ab4dc18bf7a5a4"
    }
  },
  {
    "ts": null,
    "headline": "Duchenne Muscular Dystrophy Drugs Market Global Forecast 2025-2032: Sarepta, Pfizer, BioMarin, Roche, Bayer, Solid Biosciences, Cytokinetics, and NS Pharma Drive Innovation and Commercial Expansion",
    "summary": "The Duchenne Muscular Dystrophy Drugs Market presents opportunities in advanced genetic therapies, digital health, and adaptive models amid rising global demand. Strategic alliances, resilient supply chains, and localized strategies are key in navigating regulatory shifts and achieving competitive differentiation in diverse regions. Duchenne Muscular Dystrophy Drugs Market Duchenne Muscular Dystrophy Drugs Market Dublin, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The \"Duchenne Muscular Dystrophy Drugs Ma",
    "url": "https://finnhub.io/api/news?id=f6026150ecd01b4acbfdaf99b1460c761ca2a6b4fc5a5277684b57390b3f35ad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759996860,
      "headline": "Duchenne Muscular Dystrophy Drugs Market Global Forecast 2025-2032: Sarepta, Pfizer, BioMarin, Roche, Bayer, Solid Biosciences, Cytokinetics, and NS Pharma Drive Innovation and Commercial Expansion",
      "id": 137028778,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Duchenne Muscular Dystrophy Drugs Market presents opportunities in advanced genetic therapies, digital health, and adaptive models amid rising global demand. Strategic alliances, resilient supply chains, and localized strategies are key in navigating regulatory shifts and achieving competitive differentiation in diverse regions. Duchenne Muscular Dystrophy Drugs Market Duchenne Muscular Dystrophy Drugs Market Dublin, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The \"Duchenne Muscular Dystrophy Drugs Ma",
      "url": "https://finnhub.io/api/news?id=f6026150ecd01b4acbfdaf99b1460c761ca2a6b4fc5a5277684b57390b3f35ad"
    }
  }
]